For research and education only · Not reviewed by a medical professional · Disclaimer

← PepsRadar home

Research field guide

What happens when you stop semaglutide? What the trials show

Content updated · how dates work

In the trials, most people who stopped semaglutide (Ozempic, Wegovy) regained much of the weight within a year, and gains in blood pressure and blood sugar faded too. The numbers from STEP 1, STEP 4 and tirzepatide’s SURMOUNT-4, and what the evidence says may help.

PepsRadar editorial · November 12, 2026 · Original, AI-assisted guide · Not reviewed by a medical professional

About two-thirds of lost weight was regained in the year after stopping semaglutide and lifestyle support (STEP 1 extension)

Quick answers

What happens when you stop semaglutide?
In the trials, most people regained much of the weight within about a year. In the STEP 1 extension, people regained about two-thirds of what they had lost in the year after stopping, though they still weighed 5.6% less than when they started. Blood pressure and blood sugar also drifted back toward their starting values.
How much weight comes back after stopping?
In STEP 4, people switched to placebo after 20 weeks of semaglutide regained 6.9% of their weight over the next 48 weeks, while those who kept taking it lost a further 7.9%.
Does the same happen with tirzepatide?
Yes. In SURMOUNT-4, people switched to placebo after 36 weeks of tirzepatide regained 14.0% of their body weight over a year, while those who continued lost another 5.5%.
What helps keep weight off after stopping?
Exercise has the best evidence so far. In a small Danish trial with liraglutide, an older GLP-1 medicine, people who combined it with supervised exercise kept off about 5 kg more a year after treatment ended than those who took the medicine alone. Plans to stop are best made with a prescriber.
01

The short answer

In the clinical trials, people who stopped semaglutide regained most of the weight they had lost within about a year, and most heart and metabolic measures, such as blood pressure and blood sugar, drifted back toward where they started. The same pattern shows up with tirzepatide.

That doesn’t mean the medicine stopped working. These drugs reduce appetite while they are taken, and appetite tends to return when they stop. The STEP 1 extension authors concluded that their findings confirm obesity is a chronic condition and suggest ongoing treatment is needed to keep the improvements.

Source: STEP 1 extension, Wilding et al., Diabetes Obes Metab 2022 ↗

02

STEP 1 extension: one year off treatment

After the main STEP 1 trial, 327 participants were followed for a year with no medicine and no lifestyle program. Over the 68 weeks of treatment they had lost 17.3% of their body weight on semaglutide versus 2.0% on placebo.

A year after stopping, the semaglutide group had regained 11.6 percentage points, leaving them 5.6% below their starting weight. In other words, they regained about two-thirds of what they had lost, though they still weighed less than when they began. Most heart and metabolic measures, such as blood pressure and blood sugar, moved back toward their starting values.

One caution: the lifestyle support ended at the same time as the medicine, and this was a subset of the original trial, so it shows what happens when everything stops at once.

Source: STEP 1 extension, Wilding et al., Diabetes Obes Metab 2022 ↗

03

STEP 4: switching to placebo partway through

STEP 4 tested stopping directly. 803 adults took semaglutide for 20 weeks and lost an average of 10.6%. They were then randomly assigned either to keep taking it or to switch, without knowing, to a placebo for another 48 weeks.

Those who continued lost a further 7.9% of their weight. Those switched to placebo gained 6.9% back, a 14.8-point difference. Waist size and blood pressure also favored continuing. Stomach and gut side effects were more common on semaglutide (49.1% versus 26.1%), but few people in either group stopped because of side effects (2.4% versus 2.2%).

Source: Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. ↗

04

Tirzepatide shows the same pattern

SURMOUNT-4 ran the same kind of test with tirzepatide (Zepbound). After 36 weeks of treatment and an average 20.9% weight loss, 670 adults were randomly assigned to continue or switch to placebo for a year.

The placebo group regained 14.0% of their body weight, while the tirzepatide group lost another 5.5%. At the end, 89.5% of those who continued had kept at least 80% of their earlier weight loss, versus 16.6% of those switched to placebo.

Source: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. ↗

05

What may help keep weight off

Exercise is the best-studied option. In a Danish trial, adults who had lost weight on a low-calorie diet were assigned to supervised exercise, liraglutide (an older GLP-1 medicine), both, or placebo for a year, and then followed for a year with no treatment. Those who had done both kept off about 5 kg more than those who had taken liraglutide alone, and people who had exercised were more likely to keep off at least 10% of their weight.

That trial was small (109 people in the follow-up) and used liraglutide rather than semaglutide, so it is a signal, not proof. Whether to continue, step down or stop a GLP-1 medicine, and how to plan for it, is a decision to make with a prescriber. PepsRadar gives no dosing or treatment advice.

Source: Jensen et al., eClinicalMedicine 2024 ↗

Continue with the original research

Study examples are based on selected publication abstracts and the explicitly described source documents. This is not a systematic review or an individualized treatment guide. Editorial scope and methods.

See something wrong on this page? Report a mistake · Corrections